Login to Your Account

Deals And M&A NEWS

TAIPEI – Taipei-based OBI Pharma Inc. has entered a deal with Merck & Co. Inc. for the development and commercialization in Taiwan of its narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin), which is used to treat Clostridium difficile-associated diarrhea.

Drug developers, Biscayne Pharmaceuticals Inc. and Insero Health Inc., have merged to advance a synthetic version of a traditional Chinese medicine – into phase Ib/IIa proof of concept in epilepsy by mid- to late 2016.

Teva Pharmaceutical Industries Ltd. has agreed to acquire Representaciones e Investigaciones Médicas (Rimsa), of Mexico City, in a deal valued at $2.3 billion that will position the Israeli firm as the leading pharmaceutical company in Mexico.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: